Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Medicines Data Standards Offer Business Opportunities For Life Science Firms

Executive Summary

The newly published EU IDMP guide on implementing ISO data standards for the identification of medicinal products will keep regulatory affairs professionals busy with compliance work while also creating new data-driven opportunities for life sciences companies. Remco Munnik shares the inside track from his work with the EU focus group that created the guide.

You may also be interested in...



Beiersdorf Is Having Record Year For Sun Care, Seeing China Recovery, But Full-Year Outlook Is Guarded

The Hamburg, Germany-based firm defied economic and political headwinds and China troubles in the fiscal 2022 first half to book organic net sales growth of 10.5% to 4.5bn worldwide. Despite optimism about China recovery, sun care, and its recent Chantecaille acquisition, Beiersdorf is projecting a slowdown in the second half in what remains a volatile operating environment.

Don’t Believe The Lack Of Hype: US Drug Price Reform Is Biggest Ever

The narrative about the Democrats’ march toward comprehensive drug pricing legislation in the US has emphasized what has dropped out of the original proposal. That obscures the bigger picture: it will be by far the most impactful drug pricing legislation ever enacted in the US.

Part D Price Negotiation Round One: Several Likely Candidates May Not Feel The Cut

Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel